
Patrick Hensley, MD
@pjhensley11
Urologic Oncologist at the University of Kentucky. Bladder cancer researcher. Husband and father x3.
ID: 3083982069
10-03-2015 13:36:52
183 Tweet
395 Followers
215 Following


Impressive results Mark Tyson ; yet another option for our patients and … even more reason to start doing RCTs in BCG unresponsive with these agents #bladdercancer #SUO23 Roger Li Gary Steinberg Max Kates Peter Black UroToday.com IBCG Matt Galsky Patrick Hensley, MD

Such a privilege to have Dr. Kamat Ashish M. Kamat, MD, MBBS as part of the Society of Urologic Oncology SUO Visiting Professor and University of Kentucky Urology Residency Program Bruce Lucas Visiting Professor. Lots of knowledge gained from interactive discussions regarding bladder cancer and there was no better person to lecture us on this topic!


Even with some technical difficulties, SethTepUro dropping knowledge on prognostic significance of path response to NAC in variant histology MIBC. University of Kentucky Urology Residency Program #AUA24


What is the role of restaging TURBT for HG Ta disease? There exists considerable uncertainty in a room full of bladder cancer experts. Time for a RCT?IBCG #bladdercancer Ashish M. Kamat, MD, MBBS Jeremy Teoh Neal shore Badrinath Konety, MD, MBA Mark Tyson


We are truly a global organization Not just words, deeds #AUA24 #TogetherWeRise Karima Oualla, MD,MSc Shilpa Gupta Ashish M. Kamat, MD, MBBS Amanda Myers Janet Kukreja Petros Grivas Roger Li Patrick Hensley, MD Sima Porten Amer. Urol. Assn.

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by Amanda Myers


Treatment Options for Advanced Urothelial Cancer urotoday.com/video-lectures… Shilpa Gupta Patrick Hensley, MD IBCG UroToday.com



Defining standard and extended pelvic lymphadenectomy in #BladderCancer surgery. Seth Lerner, MD, FACS BCMHouston & Sia Daneshmand, M.D. Keck Medicine of USC join Patrick Hensley, MD as part of the IBCG #BladderCancerForum in this discussion on UroToday > bit.ly/3VjRpuM


Clinical Validation of the Intermediate-risk NMIBC Scoring System and Substratification Model Proposed by the IBCG (International Bladder Cancer Group): A Multicenter YAU Urothelial Working Group Collaboration European Urology Oncology Paolo Gontero francesco soria authors.elsevier.com/c/1jIAG9Cfv--d… a🧵


Only two weeks until the #IBCG24 Retreat! Looking forward to welcoming top bladder cancer experts, dedicated patient advocates and partners from around the globe to Houston The retreat chaired by Roger Li Patrick Hensley, MD Shilpa Gupta is all about collaboration: together, we’ll


Development and Validation of a Multivariable Nomogram Predictive of Post-Nephroureterectomy Renal Function by Patrick Hensley, MD, Craig Labbate et al Full article: buff.ly/4ixpTDO #UroSoMe #MedTwitter #EUO


Proud of Joon Kyung Kim, MD 김준경 and University of Kentucky Urology Residency Program for presenting impactful work at #GU25! Markey Cancer Center



Tremendous discussion with #matosgu25 bladder cancer thought leaders on rapidly changing perioperative MIBC systemic tx! Petros Grivas Bogdana Schmidt MD, MPH Chad Tang, MD Jonathan Rosenberg MD 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏


Join us for the AUA-IBCG Bladder Cancer Forum April 28, 2–5 pm 🗓️ #AUA25 Amer. Urol. Assn. IBCG Kelly Bree Petros Grivas Laura Bukavina Shilpa Gupta Neha Vapiwala Wes Kassouf Peter Black Patrick Hensley, MD Hikmat Al Ahmadie Joshua Meeks Benjamin Pradere Sia Daneshmand, M.D. Vignesh Packiam, MD


Optimizing patient selection and treatment timing with emerging intravesical therapies: the case of nadofaragene firadenovec. Patrick Hensley, MD The University of Kansas Department of Urology sits down with Sam S. Chang MD, MBA Vanderbilt Urology sharing insights on nadofaragene firadenovec, from operational improvements to patient


#AUA25 Highlights: Advances in #NMIBC. Patrick Hensley, MD & Janet Kukreja join Sam S. Chang MD, MBA highlighting three major BCG-unresponsive CIS trials 🔹 BCG-unresponsive CIS: – Anktiva+BCG: 71% CR – CG0070 (BOND-003): 76% ORR – TAR-200 (SunRISe-1): 82% response 🧠 Surprise: #CISTO shows